RT Journal Article
T1 Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.
A1 Martinez-Cuadron, David
A1 Serrano, Josefina
A1 Mariz, Jose
A1 Gil, Cristina
A1 Tormo, Mar
A1 Martinez-Sanchez, Pilar
A1 Rodriguez-Arboli, Eduardo
A1 Garcia-Boyero, Raimundo
A1 Rodriguez-Medina, Carlos
A1 Martinez-Chamorro, Carmen
A1 Polo, Marta
A1 Bergua, Juan
A1 Aguiar, Eliana
A1 Amigo, Maria L
A1 Herrera, Pilar
A1 Alonso-Dominguez, Juan M
A1 Bernal, Teresa
A1 Espadana, Ana
A1 Sayas, Maria J
A1 Algarra, Lorenzo
A1 Vidriales, María B
A1 Vasconcelos, Graça
A1 Vives, Susana
A1 Perez-Encinas, Manuel M
A1 Lopez, Aurelio
A1 Noriega, Victor
A1 Garcia-Fortes, María
A1 Chillon, Maria C
A1 Rodriguez-Gutierrez, Juan I
A1 Calasanz, Maria J
A1 Labrador, Jorge
A1 Lopez, Juan A
A1 Boluda, Blanca
A1 Rodriguez-Veiga, Rebeca
A1 Martinez-Lopez, Joaquin
A1 Barragan, Eva
A1 Sanz, Miguel A
A1 Montesinos, Pau
K1 FLT3-ITD mutation
K1 Acute myeloid leukemia
K1 Real-world outcomes
K1 Relapsed/refractory disease
K1 Salvage therapy
AB This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (p< 0.001). In the overall population, median overall survival (OS) was 5.5 months; 1- and 5-year OS rates were 25% and 7%. OS was significantly (p < 0.001) prolonged with intensive or non-intensive salvage therapycompared with supportive therapy, and in those achieving CR/CRi versus no responders. Of 280 evaluable patients, 61 (22%) had an allogeneic stem-cell transplant after they had achieved CR/CRi. In conclusion, in this large cohort study, salvage treatment approaches for patients with FLT3-ITDmutated R/R AML were heterogeneous. Median OS was poor with both non-intensive and intensive salvage therapy, with best long-term outcomes obtained in patients who achieved CR/CRi and subsequently underwent allogeneic stem-cell transplant.
PB MDPI
SN 2072-6694
YR 2022
FD 2022-05-31
LK http://hdl.handle.net/10668/20901
UL http://hdl.handle.net/10668/20901
LA en
NO Martínez-Cuadrón D, Serrano J, Mariz J, Gil C, Tormo M, Martínez-Sánchez P, et al.  Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia. Cancers (Basel). 2022 Jun 6;14(11):2817
DS RISalud
RD Apr 12, 2025